Bertilimumab

From Self-sufficiency
Revision as of 18:48, 27 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Bertilimumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CCL11 (eotaxin-1)
Identifiers
CAS Number 375348-49-5
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1.

It was discovered by Cambridge Antibody Technology using their phage display technology[1]. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders[2].

In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.[3]. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'[4].

iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis[5].

In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.[6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Intracellular
(initiation)
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)
"-limu-" (immune system)
"-kinu-" (interleukin as target)
"-tumu-"/"-tu-" (tumor)
"-osu-" (bone)
"-mulu-" (musculoskeletal)
"-fungu-" (fungal)
"-viru-" (viral)
"-bacu-" (bacterial)
"-ciru-" (cardiovascular)
"-neru-" (neurologic)


40x30px This monoclonal antibody-related article is a stub. You can help ssf by expanding it.
40px This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.
  1. ↑ http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395
  2. ↑ http://www.ncbi.nlm.nih.gov/pubmed/15573873
  3. ↑ http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/
  4. ↑ http://www.icotherapeutics.com/site/corporate_overview/overview/
  5. ↑ http://www.icotherapeutics.com/site/pipeline/ico008/
  6. ↑ http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Bertilimumab&oldid=23055"